Imunon, Inc. Q1 FY2025 earnings call

• Initiated the first clinical site in Phase III pivotal study of Imunon-001 (OVATION 3) for ovarian cancer. - OVATION 2 results accepted for oral presentation at ASCO Annual Meeting and publication in Gynecologic Oncology. - New translational data from OVATION 2 to be presented at International ESMO Gynecological Conference. - PlaCCine technology has advantages like exceptional stability, rapid adaptation, longer lasting protection, and cost-effective manufacturing. - Pulled manufacturing of core active pharmaceutical ingredients in-house for OVATION 3 trial.

No specific product segments with detailed financial performance and revenue contribution provided. Research and development costs were $2.2 million for Q1 2025 vs $3.3 million in Q1 2024, due to lower costs from PlaCCine trial. General and administrative expenses were $2 million in Q1 2025 vs $1.7 million in Q1 2024, due to higher employee-related expenses. Net loss was $4.1 million or $0.28 per share in Q1 2025 vs $4.9 million or $0.52 per share in Q1 2024.

• Focus on securing near-term financing to strengthen financial condition and advance OVATION 3. - Goal to cover OVATION 3 trial costs through corporate partnerships and equity. - Expect update on financing by end of current quarter.

Q: Congrats on ASCO presentation, any new subgroup analysis or median OS for HRD positive patients at ASCO?

A: By ASCO's embargo, can't discuss content, but excited about presentation.

Q: How many sites for Phase III trial and OS dual primary endpoint?

A: Analysis predicated on HRD population first. Projecting about 45 sites. OS is primary for all populations.

Q: Current status of inventory and manufacturing for OVATION 3 trial?

A: Pulled manufacturing in-house, prepared and monitoring enrollment plans with product available.

Q: Status of trial with Breakthrough Cancer Foundation and preliminary results?

A: Meeting PIs every two weeks, initiated another site, expecting data end of year.